Trial Profile
PAzopanib Real-world Assessment of Clinical effectiveness and safety in patients wHo have Undergone Treatment in different sEttings in advanced renal cell carcinoma; a prospective, non-interventional, observational study - PARACHUTE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Oct 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PARACHUTE
- Sponsors Novartis Healthcare; Novartis Pharmaceuticals Corporation
- 14 Sep 2021 Status changed from recruiting to completed as per results published in the BMC Cancer
- 14 Sep 2021 Results published in the BMC Cancer
- 21 Aug 2017 Status changed from not yet recruiting to recruiting.